Results 161 to 170 of about 881,158 (314)

SERPINA1 is a new frontier in cancer immunotherapy and drug targeting by pan-cancer analysis. [PDF]

Discov Oncol
Fu C, Hu Y, Yang L, Sun W.
europepmc   +1 more source

Iron oxide nanoparticles in magnetic drug targeting and ferroptosis-based cancer therapy. [PDF]

Med Rev (2021), 2023
Shubhra QTH.
europepmc   +1 more source

A multi-targeted In Silico approach to select and rank regenerative drugs for managing diabetic wound inflammation signalling through IGFR, TNFR and PPAR -γ pathways [PDF]

Lakshmi Priyadarsini S, L Sreelakshmi, S. Adebisi S., G. Prakash   +3 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP

Annals of Hepatology, 2015
Marta R. Romero, Maria J. Monte, Jose J.G. Marin, Ph.D.   +2 more
doaj   +1 more source

Influence of PEG Molecular Weight on Washout Resistance and Deposition Efficiency of Magnetoresponsive Nanoclusters Under Pulsatile Flow for Magnetic Drug Targeting. [PDF]

Pharmaceuticals (Basel)
Bernad SI, Bernad ES.
europepmc   +1 more source

Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets [PDF]

, 2017
Xin Wang, Pablo Binder, Qiru Fang, Zhenzhong Wang, Wei Xiao, Wei Liu, Xin Wang   +6 more
openalex   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Neutral pH-Selective Inhibition of Cytosolic Cathepsin B: A Novel Drug Targeting Strategy for Traumatic Brain Injury and Alzheimer's Disease. [PDF]

ACS Chem Biol
Hook V, Podvin S, Yoon MC, Phan VV, Florio J, Spencer B, Mosier C, Cheng A, Ahuett S, Almaliti J, Gerwick WH, Rissman RA, O'Donoghue AJ.   +12 more
europepmc   +1 more source

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site [PDF]

, 2018
Eirinaios I. Vrettos, Gábor Mező, Andreas G. Tzakos   +2 more
openalex   +1 more source